Lab-grown patient cells help test drugs for rare diseases
In short
- Researchers model patients' diseases in the lab using human-derived iPS cells.
- Candidate drugs can be evaluated directly in those cells, including for rare diseases.
- In February 2026 Japan announced a manufacturing system for an iPS cell-based spinal cord injury therapy.
Why it's good news
Rare diseases affect small numbers of patients, so drugs for them are often slow to develop. Testing candidates in cells taken from patients offers a more direct route than relying on animal models alone. The February 2026 manufacturing announcement suggests the approach is moving from research toward clinical use, though the source does not say when a therapy will reach patients.
From nippon.com
By modeling patients’ diseases in the laboratory and evaluating candidate drugs directly in human-derived cells, researchers like Okano Hideyuki of Keiō University are using iPS cells to open a new era in drug discovery. With Japan’s February 2026 announcement of a manufacturing system for an iPS cell-based therapy for spinal cord injury, the field is now entering a new phase of real-world implementation.